All In Biotech

Drug Trial Radar · NCT05734040

Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.

Phase 2a, Randomized, Double-blind (Double-dummy), Double Placebo-controlled, Parallel-group Study to Evaluate the Immunogenicity and the Safety of the Concomitant Administration of OVX836 Influenza Vaccine and Quadrivalent Inactivated Influenza Vaccines (QIVs: Fluarix Tetra and Afluria Quad) Given Intramuscularly as 2 Separate Injections Into Opposite Arms, in Comparison to the Concomitant Administration of Quadrivalent Inactivated Influenza Vaccines and Placebo, and OVX836 and Placebo Given the Same Way in Healthy Subjects Aged 18 to 60 Years.

Last checked: Nov 19, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 478 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

478

Actual

Start

May 10, 2023

Primary completion

Aug 10, 2023

Study completion Jan 15, 2024

Sponsor

Lead sponsor
OsivaxIndustry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited; Mater Misericordiae Limited
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The present study OVX836-006 aims principally to: * Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e. as two separate concomitant injections into opposite arms; * Introduce an additional representative brand of Quadrivalent Inactivated Influenza Vaccines ; * Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the Hemagglutinin response; * Demonstrate the absence of interaction between OVX836 and Quadrivalent Inactivated Influenza Vaccines on the nucleoprotein response; * Evaluate the absolute vaccine efficacy of OVX836 compared to placebo in order to corroborate the efficacy signals previously detected in the OVX836 previous studies; * Evaluate the combined vaccine efficacy of OVX836 + Quadrivalent Inactivated Influenza Vaccines versus OVX836 + placebo, and versus double placebo.

Conditions

  • Influenza

Interventions

  • OVX836 480µgBiological

    One single administration intramuscularly at Day 1

  • Fluarix TetraBiological

    One single administration intramuscularly at Day 1

  • Afluria QuadBiological

    One single administration intramuscularly at Day 1

  • PlaceboBiological

    One single administration intramuscularly at Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of seroconversion determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Inactivated Influenza Vaccines.Time frame: At Day 29 versus pre-injection baseline (Day 1)
  2. Proportion of subjects achieving a titer ≥1:40 at Day 29 determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Inactivated Influenza Vaccine.Time frame: At Day 29
  3. Number of Hemagglutination-Inhibition assay titers geometric mean ratios >2.5 for the four influenza strains contained in the Quadrivalent Inactivated Influenza Vaccines.Time frame: At Day 29 versus pre-injection baseline (Day 1)
  4. Proportion of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic signs and symptoms (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever)Time frame: During 7 days after vaccine administration
  5. Proportion of subjects reporting unsolicited Adverse EventsTime frame: During 29 days after vaccine administration
  6. Proportion of subjects reporting Serious Adverse EventsTime frame: During the whole study duration, 180 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Paratus Clinical Research Central Coast

    Kanwal, New South Wales, Australia

  • Emeritus Research Sydney

    Sydney, New South Wales, Australia

  • Paratus Clinical Research Western Sydney

    Sydney, New South Wales, Australia

  • Paratus Clinical Research Brisbane

    Brisbane, Queensland, Australia

  • Mater Misericordiae Limited

    Brisbane, Queensland, Australia

  • UniSC Clinical Trials Moreton Bay

    Morayfield, Queensland, Australia

  • University of Sunshine Coast

    Sippy Downs, Queensland, Australia

  • CMAX Fusion Clinical Research

    Adelaide, South Australia, Australia

  • Emeritus

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.